Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person4
UroGen Pharma Ltd.
Company
Nasus Pharma Ltd
Company
Kairos Pharma, LTD.
Company
Medicus Pharma Ltd.
Company
Primary record4
UroGen Pharma Ltd. filed 8-K
Item 2.02 Results of Operations and Financial Condition On November 4, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2026. A copy of the press release is att
BlackRock, Inc. filed SCHEDULE 13G/A
0002012383-26-003732.txt : 20261027 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0002012383 XXXXXXXX LIVE 1 Common Stock 09/30/2026 0001668243 UROGEN PHARMA LTD M96088105 400 Alexander Park Drive, 4th Floor Prin
UroGen Pharma Ltd. filed 8-K
Item 8.01 Other Events. On August 18, 2026, UroGen Pharma Ltd. (“the Company”), through its wholly owned subsidiary UroGen Pharma, Inc. (“UroGen U.S.”), entered into an Option and Research License Agreement (the “Option
UroGen Pharma Ltd. filed SCHEDULE 13G/A
or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of